Background Global antiretroviral therapy has entered a new era. Integrase strand transfer
inhibitor (INSTI) has become the first choice in acquired immunodeficiency syndrome (AIDS) …

Objective: To describe weight changes with integrase strand transfer inhibitor (INSTI)
therapy. Data Sources: A literature search was performed (through December 15, 2021) …

Objective Evidence suggests that integrase strand transfer inhibitors (INSTIs) are associated
with greater weight gain than other antiretrovirals. This real-world study compares …

Background Treatment initiation with integrase strand transfer inhibitors (INSTIs) has been
associated with excess weight gain. Whether similar gains are seen after switch to INSTIs …

Background Studies have shown an increase in weight among people living with human
immunodeficiency virus (PLWH) who have also initiated integrase strand transfer inhibitors …

Background Excessive weight gain in patients living with HIV (PLWH) can have
considerable health-related consequences. Recent observational studies suggest that …

Background Integrase strand-transfer inhibitor (INSTI)-based antiretroviral therapy (ART) is
recommended for human immunodeficiency virus (HIV) management. Although studies …

Introduction: Post-marketing data have demonstrated the potential for weight gain with
integrase inhibitors (INSTI) use in antiretroviral (ART) therapy. Methods: A medical chart …

Background This study explored the relationship between integrase strand transfer inhibitor
(INSTI)-based anti-retroviral agents and weight gain over time, and the risk factors for weight …

Background: The use of integrase inhibitor-based antiretroviral therapy could be associated
with worse weight and metabolic outcomes in patients with HIV infection. Methods: PubMed …